340B Advocacy Alliance Bulletin

The AHA today urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s proposed 340B rebate model pilot program, saying the agency’s projection of five hours of work per week significantly understates the real-world…

The AHA today urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s proposed 340B rebate model pilot program, saying the agency’s projection of five hours of work per week significantly understates the real-world…

The AHA today released legislative advisories on a 340B bill introduced by a bipartisan House working group and a legislative discussion draft introduced in the Senate.

If you haven’t done so yet, please register for an AHA 340B Advocacy Alliance call on July 8 at 3 p.m. ET to hear the latest updates on the 340B Drug Pricing Program.

The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.4% in calendar year 2027 compared to CY 2026.

Join the AHA 340B Advocacy Alliance on July 8 at 3 p.m. ET for the latest updates on the 340B Drug Pricing Program and opportunities to engage directly with AHA 340B team members.

Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a legislative discussion draft that would make several changes to the 340B Drug Pricing Program.

HRSA seeks input on 340B Rebate Model.

The AHA today issued a statement denouncing unprecedented actions taken by Eli Lilly to deny 340B Drug Pricing Program discounts to certain 340B hospitals that do not meet its unilateral data requirements.

HRSA seeks input on 340B Rebate Model.